Obesity Treatment Is Changing: What Clinical Trials Tell Us About GLP-1–Based Therapies

Obesity has now been recognized as a chronic, complicated disease rather than simply a condition caused by specific individual lifestyle factors and choices. The World Health Organization has demonstrated that more than 1 billion people were living with obesity worldwide in the year 2022, whereas obesity has been associated with serious health comorbidities that include several factors like cardiovascular disease, type 2 diabetes, and certain cancers. The rising health stresses have enhanced the requirements for interventions and treatments that can result in meaningful, impactful, and controlled weight loss alongside lifestyle modifications.

Furthermore, key major developments have been assessed during the clinical testing and evaluation of GLP-1 receptor agonists, especially the one named semaglutide. As observed in the phase 3 STEP 1 clinical trial, 1,961 adults being overweight or with obesity and without diabetes were randomly allotted to once-a-week semaglutide (2.4 mg) or placebo along with lifestyle modification for 68 weeks. Participants that were receiving semaglutide encountered a mean body-weight decrease of 14.9%, as compared with 2.4% with placebo, clearly demonstrating significant effectiveness in the process of weight management. 

This trial also shows why randomized controlled trials are significant. Rather than having the assumption of how a treatment works, researchers essentially compare it with a placebo under sustained conditions and assess pre-established results.

Significantly, later trials have gone beyond simply questioning whether these medicines actually cause weight reduction and have examined whether they can enhance the major clinical outcomes. In addition, the SELECT trial registered 17,604 adults with defined comorbidities such as cardiovascular disease, overweight or obesity, and no diabetes. Furthermore, post mean follow-up of almost 40 months, major cardiovascular events were reported in 6.5% of participants who were receiving semaglutide in comparison with 8.0% who were receiving placebo, also observed a hazard ratio of 0.80. 

Additionally, the phase 3 SURMOUNT-1 trial explored tirzepatide, a dual GIP/GLP-1 receptor agonist, in the population of 2,539 adults dealing with obesity or overweight and a weight-based complication. At around 72 weeks, the mean weight decrease as observed ranged from 15.0% to 20.9% across the results seen in tirzepatide doses in comparison with 3.1% as observed with placebo.

Altogether, these trials illustrate how modern clinical research is actually transforming the obesity management from an essentially lifestyle-based approach toward a practically evidence-based, pharmacological long-term process of disease management. Nevertheless, clinical trials also outline the significance of evaluating various factors like safety, common adverse effects, sustained long-term outcomes, several treatment discontinuation protocols, and most importantly, the results of whether these benefits remain post-treatment. Additionally, future research studies will be needed to essentially determine which kind of patients actually benefit the most, how these therapies should be utilized over chronic long-term conditions, and how pharmacological treatment can be incorporated with nutrition, physical activities, and comprehensive and multifactorial programs.

References — APA 7th Edition

Conti C. R. (2018). Obesity and Weight Loss. European cardiology, 13(2), 93–94. https://doi.org/10.15420/ecr.2018.13.2.EO1

Kim J. Y. (2021). Optimal Diet Strategies for Weight Loss and Weight Loss Maintenance. Journal of obesity & metabolic syndrome, 30(1), 20–31. https://doi.org/10.7570/jomes20065

Bray, G. A., & Ryan, D. H. (2021). Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes. Diabetes, obesity & metabolism, 23 Suppl 1, 50–62. https://doi.org/10.1111/dom.14200